Ultime notizie per Nuvalent (NASDAQ:NUVL) Azioni

Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Nuvalent Inc

Nuvalent jumps 19% on $350M equity offering

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Nuvalent (NUVL – Research Report). The company's shares closed last...

Nuvalent (NUVL) Receives a Buy from TD Cowen

Nuvalent announces pricing of $500M upsized stock offering

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

New small-cap buy and sell ideas for Oppenheimer's 50/50 list

The deal priced below last closing price of $102.51. JPMorgan is acting as sole book running manager for the offering. Published first on TheFly – ...

Nuvalent 2M share Spot Secondary priced at $99.00

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

APLE

BPMC

CATX

CGEM

CGON

CWEN

HAFC

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NRIX

NUVL

PATK

RHHBF

RHHBY

RHHVF

SIRI

SNDX

VKTX

Earnings

Press Releases

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Offerings

Nuvalent Announces Public Offering of Common Stock

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

NVCT

SMMT

Arcellx

ADMA Biologics

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Viking Therapeutics

JP Morgan

Guggenheim

Wedbush

BMO Capital

Comments

Nuvalent

Notizie

Ultime notizie per Nuvalent (NASDAQ:NUVL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO